0001551259-17-000001.txt : 20170628
0001551259-17-000001.hdr.sgml : 20170628
20170628160320
ACCESSION NUMBER: 0001551259-17-000001
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20170628
DATE AS OF CHANGE: 20170628
EFFECTIVENESS DATE: 20170628
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: EMERGE DIAGNOSTICS, INC
CENTRAL INDEX KEY: 0001551259
IRS NUMBER: 900849392
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-289636
FILM NUMBER: 17935230
BUSINESS ADDRESS:
STREET 1: 5924 BALFOUR CT.
STREET 2: SUITE 102
CITY: CARLSBAD
STATE: CA
ZIP: 92008
BUSINESS PHONE: 866-878-2597
MAIL ADDRESS:
STREET 1: 5924 BALFOUR CT.
STREET 2: SUITE 102
CITY: CARLSBAD
STATE: CA
ZIP: 92008
FORMER COMPANY:
FORMER CONFORMED NAME: EMERGE DIAGNOSTICS, LLC
DATE OF NAME CHANGE: 20140620
FORMER COMPANY:
FORMER CONFORMED NAME: OKTX, LLC
DATE OF NAME CHANGE: 20120531
D
1
primary_doc.xml
X0707
D
LIVE
0001551259
EMERGE DIAGNOSTICS, INC
5924 BALFOUR CT.
SUITE 102
CARLSBAD
CA
CALIFORNIA
92008
866-878-2597
DELAWARE
EMERGE DIAGNOSTICS, LLC
OKTX, LLC
Corporation
true
Robert
Thompson
5924 Balfour Ct., Suite 102
Carlsbad
CA
CALIFORNIA
92008
Executive Officer
Director
Jerry
Wilkins
5924 Balfour Ct., Suite 102
Carlsbad
CA
CALIFORNIA
92008
Executive Officer
Director
Mary Rose
Reaston
5924 Balfour Ct., Suite 102
Carlsbad
CA
CALIFORNIA
92008
Executive Officer
Phil
Reaston
5924 Balfour Ct., Suite 102
Carlsbad
CA
CALIFORNIA
92008
Executive Officer
Michael
Connor
5924 Balfour Ct., Suite 102
Carlsbad
CA
CALIFORNIA
92008
Director
Murray
Lappe
5924 Balfour Ct., Suite 102
Carlsbad
CA
CALIFORNIA
92008
Director
David
Miller
5924 Balfour Ct., Suite 102
Carlsbad
CA
CALIFORNIA
92008
Director
William
Quirk
5924 Balfour Ct., Suite 102
Carlsbad
CA
CALIFORNIA
92008
Director
Scott
Wolesson
5924 Balfour Ct., Suite 102
Carlsbad
CA
CALIFORNIA
92008
Director
Mark
Sampson
11611 San Vicente Blvd
Suite 1000
Los Angeles
CA
CALIFORNIA
90049
Director
Other Health Care
Decline to Disclose
- 06b
false
2017-06-12
false
true
true
true
true
false
0
8000000
250000
7750000
Tranche 1 consists of the sale of up to $7mm of newly issued Series E Preferred Stock; Tranche 2 consists of the purchase of up to $1mm of Series E Preferred Stock.
false
1
0
0
0
false
EMERGE DIAGNOSTICS, INC
/s/ Robert D. Thompson
Robert D. Thompson
Chief Executive Officer
2017-06-28